Translating Induced Proximity, AutoTAC, PROTAC & Other TPDs Into the Clinic to Target Neurodegeneration & Neuro-Oncology
The Protein Degradation for CNS Summit returns to Boston for its 2nd year running. With this ever-progressing field in neurodegenerative disease drug development, the design of protein degradation therapies has gained huge amounts of momentum. With the first patient dosed by Arvinas, the movement towards clinic has rapidly changed the focus of the field towards translating towards Phase I trials.
Be a part of the future of protein degradation for CNS diseases by keeping your knowledge up-to-date. Hear the latest findings in degrader design, target identification, mechanism selection and PKPD considerations at this industry-leading conference, with expert speakers from Arvinas, Biogen and Monte Rosa Therapeutics.
Download the Full Event Guide for more information on:
- 20+ Biotech & Pharma Speakers
- 4 Interactive Deep-Dive Workshops
- 6+ Hours of Networking
- & Much More!
Emiliano Biasini
Co-Founder (Sibylla,) & Associate Professor
Centre for Integrative Biology (Cibio), University of Trento
Past Attendees Included:
Testimonial:
“The pre-conference day was very useful in introducing both protein degradation and CNS basics to those new to both areas. The breadth and diversity of presentations was outstanding. The level of questions and networking was very educational” Origami Therapeutics
Origami Therapeutics
Other Events in the Series:
